[Click eStock] "WSI, Reassessed as a Medical Robot Company with Ubot"

GL Research announced on the 13th that DoubleWSI is concretizing its growth strategy by actively expanding new businesses based on its existing medical device and pharmaceutical distribution operations. No target price or investment opinion was provided.

Park Chang-yoon, a researcher at GL Research, stated, “Starting with the obstetrics and gynecology laparoscopic surgery and injection assist robot ‘U-BOT,’ the company plans to actively expand its medical robot business for brain and cardiovascular applications.” He added, “They have signed a memorandum of understanding (MOU) with Doosan Robotics and aim to launch the brain surgery robot and skull base robots B-BOT and E-BOT by 2026, and the cardiovascular robot C-BOT by 2028.”

He continued, “DoubleWSI entered the pharmaceutical manufacturing business by acquiring IntroBioPharma in June 2024. With its own pharmaceutical manufacturing facilities certified for Good Manufacturing Practice (GMP) and drug formulation development capabilities, stable revenue sources and profitability are expected.”

Researcher Park explained, “The company plans to actively diversify its cardiovascular interventional medical device business this year through collaborations with the UK’s Kimal, China’s Lepu, and Sunken Tech.”

DoubleWSI projects annual sales of 60 billion KRW by 2025 and plans to continue growing its medical device and pharmaceutical businesses. In particular, it aims to sell 150 units domestically and 650 units overseas of ‘U-BOT’ by 2029, strengthening its position in the global medical device market centered on the medical robot business.

This content was produced with the assistance of AI translation services.